PHASE 1B OPEN-LABEL STUDY OF ADJUVANT CUE-102, A WT-1-PHLA-IL2-FC FUSIONN PROTIEN IN GLIOBLASTOMA PATIENTS AT FIRST RECURRENCE

PI: David A. Reardon, MD
PI: David A. Reardon, M.D.
Professor of Medicine, Harvard Medical School
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute

Close Menu